丁香会议

秦叔逵：Patient-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

2013-09-26

字体大小：

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

上一张下一张

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

秦叔逵：Patent-reported Outcomes in a Registrational Study of Axitinib or Sorafenib as Second-line Therapy in Asian Patients with Metastatic Renal Cell Carcinoma

编辑：日色提来源：丁香园

大会日程

更多 >